Go offline with the Player FM app!
Preventing Myasthenic Crisis: Early Signs and Critical Interventions
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on June 06, 2025 01:14 ()
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 483885035 series 3128163
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
436 episodes
Fetch error
Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on June 06, 2025 01:14 ()
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 483885035 series 3128163
Valid until: 02-04-2026
Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.
436 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.